{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:22:33Z","timestamp":1763036553553,"version":"build-2065373602"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T00:00:00Z","timestamp":1290988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The purpose of this study was to compare 2 weekly docetaxel\u2010based regimens as first\u2010line treatments for advanced gastric cancer and to investigate the expression of secreted protein acidic and rich in cysteine (SPARC) and its abilities to predict treatment\u2010related clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients were randomly selected to receive 3 weekly cycles of docetaxel (35 mg\/m<jats:sup>2<\/jats:sup> on days 1 and 8) plus S\u20101 (35 mg\/m<jats:sup>2<\/jats:sup> each twice daily on days 1\u201014) (DS), or docetaxel plus cisplatin (35 mg\/m<jats:sup>2<\/jats:sup> each on days 1 and 8) (DC). Endpoints included overall response rate (primary), survival, toxicity, and quality of life (secondary). SPARC expression in prechemotherapy specimens of primary gastric tumors was evaluated via immunohistochemical analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Eighty patients were enrolled in the study. Confirmed overall response rates were 46% (95% confidence interval, 30%\u201062%) for DS and 24% (95% confidence interval, 11%\u201038%) for DC via intent\u2010to\u2010treat analysis. Median progression\u2010free survival was 7.3 and 4.9 months and overall survival was 16.0 and 8.3 months for DS and DC, respectively. The most common grade \u22653 toxicity was neutropenia. Grade \u22653 mucositis (18%) and hand\u2010foot syndrome (8%) were the toxicities most associated with DS, whereas anorexia (20%) and lethargy (20%) were more common with DC. High SPARC expression was related to early progression (hazard ratio, 3.67; <jats:italic>P<\/jats:italic> = .042) and poor overall survival (hazard ratio, 2.01; <jats:italic>P<\/jats:italic> = .010) in docetaxel chemotherapy on multivariate analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The outcomes in this study favored DS over DC for further phase 3 study. The findings suggest that split\u2010dose weekly docetaxel alleviates hematological toxicity without compromising efficacy, and that SPARC expression may help individualize therapy in advanced gastric cancer. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25729","type":"journal-article","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T13:23:25Z","timestamp":1291037005000},"page":"2050-2057","source":"Crossref","is-referenced-by-count":37,"title":["A randomized phase 2 study of docetaxel and S\u20101 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy"],"prefix":"10.1002","volume":"117","author":[{"given":"Hei\u2010Cheul","family":"Jeung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong Kun","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Joon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joong Bae","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Ick","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Kyung","family":"Roh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hoon","family":"Noh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Cheol","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,29]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008342013224"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2007.39.2.49"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.8429"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0135"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70035-4"},{"key":"e_1_2_7_7_2","unstructured":"ImamuraH IlishiH TsuburayaA et al.Randomized phase III study of irintoecan plus S\u20101 (IRIS) vs S\u20101 alone as fist\u2010line treatment for advanced gastric cancer (GC3031\/TOP\u2010002). Presented at: 2008 ASCO Gastrointestinal Cancers Symposium; January 25\u201027 2008; Orlando FL. Abstract 5."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2009.01191.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21879"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603196"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2425"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604312"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602213"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1247"},{"issue":"180","key":"e_1_2_7_15_2","first-page":"e1","article-title":"Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity","volume":"200","author":"Phelps SLB","year":"2009","journal-title":"Am J Obstet Gynecol."},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-004-0933-3"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-543"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2007.04.008"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2004.01898.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.17.376"},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1200\/JCO.1997.15.2.750","article-title":"Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non\u2010small cell lung cancer","volume":"15","author":"Milward MJ","year":"1997","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1071"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000086767"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb03329.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000143877.53314.9c"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000312654"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000026486.56886.18"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2004.10.006"},{"key":"e_1_2_7_29_2","first-page":"P18s","article-title":"Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first\u2010line human epidermal growth factor receptor 2 (HER2)\u2010positive advanced gastric cancer (GC)","volume":"27","author":"Van Cutsem E","year":"2009","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_7_30_2","first-page":"P15s","article-title":"Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial","volume":"27","author":"Bang YJ","year":"2009","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M706563200"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-008-0775-1"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25729","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:52:43Z","timestamp":1760269963000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,29]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,5,15]]}},"alternative-id":["10.1002\/cncr.25729"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25729","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2010,11,29]]}}}